Ottobock faced Russia lawsuit. Ottobock stock sits 34.40 percent below target

Published on 10/12/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was EUR 818.50 million in first-half 2026, up 7.70 percent. Ottobock stock costs EUR 54.45 on October 12, 2026, 34.40 percent below target.

Key points in brief

Ottobock faced a Russia-related lawsuit concerning disclosures around its business in Russia on October 7, 2026.
Jefferies retained a Buy rating and an EUR 83.00 price target on September 15, 2026.
Ottobock stock traded at EUR 54.45 at Lang & Schwarz on October 12, 2026, placing it 34.40 percent below the Jefferies target.
Core revenue reached EUR 818.50 million in the first half of 2026, up 7.70 percent.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Ottobock (ISIN DE000BCK2223) faced a Russia-related lawsuit on October 7, 2026, as finanzen.ch reported, while its stock traded at EUR 54.45 at Lang & Schwarz on October 12, 2026 at 9:47 a.m. CEST. According to finanzen.net on September 15, 2026, Jefferies retained its Buy rating and EUR 83.00 price target, leaving the stock 34.40 percent below that target at the Lang & Schwarz price.

Three milestones shape the stock

On October 9, 2025, Ottobock began trading after an IPO that raised EUR 700.00 million, according to Dr Web. On August 13, 2026, core revenue reached EUR 818.50 million in the first half of 2026, up 7.70 percent, while adjusted EBITDA rose 18.10 percent to EUR 207.00 million, the same report said. On October 7, 2026, the DSW shareholder association brought a lawsuit over whether the IPO prospectus fully described Ottobock's Russian business, with Russia accounting for 10.00 percent of revenue, finanzen.ch reported.

What does the lawsuit mean for revenue?

The legal dispute adds a disclosure risk to an operating story built on double-digit profitability improvement. NDR reported on September 25, 2026 that Ottobock rejected the allegations and reaffirmed the integrity of its capital-market information. The report also said the prospectus had been approved by BaFin in October 2025 and that the court was examining whether the case would be admitted.

For the valuation, the contrast is clear: adjusted EBITDA increased 18.10 percent to EUR 207.00 million in the first half of 2026, while Jefferies' EUR 83.00 target stands 52.43 percent above the Lang & Schwarz price. That gap makes execution, legal clarity and the next operating update the central variables in the stock's valuation.

November brings two company dates

Ottobock's next scheduled company date is November 12, 2026, when it plans to publish its quarterly statement for the third quarter. The company also lists the BNP Paribas MidCap CEO Conference on November 16, 2026. Both dates appear in the EQS News financial calendar dated September 22, 2026.

EUR 54.45 sets the market reference

Ottobock was trading at EUR 54.45 at Lang & Schwarz on October 12, 2026 at 9:47 a.m. CEST. The price lies 34.40 percent below Jefferies' EUR 83.00 target dated September 15, 2026, using the same-currency comparison. The medical technology group develops products and services in prosthetics, neuro-orthotics and exoskeletons, giving the company exposure to both recurring patient care and higher-growth bionics.

The further course of trading is shown by the continuously updated real-time quote of Ottobock stock.